10-Q: Aspire Biopharma Holdings Reports First Quarter 2025 Results Following Business Combination
Sentiment:
Quarterly Report
Aspire Biopharma Holdings reports its first quarterly results post-merger, highlighting a significant net loss and ongoing efforts to develop its sublingual drug delivery technology.
Capital raiseThe company has the right, but not the obligation, to direct Arena to purchase up to $100,000,000 in shares of the Company's common stock (the ELOC Shares) upon satisfaction of certain terms and conditions contained in the ELOC Agreement.The Company issued two 20% original issue discount senior secured convertible debentures (Debentures) in an aggregate principal amount of $3,750,000 million.
Worse than expectedThe company's net loss was significantly higher than the same period last year.The company's operating expenses increased substantially.The company's auditors have raised substantial doubt about its ability to continue as a going concern.
Summary
- Aspire Biopharma Holdings, Inc. reported its financial results for the quarter ended March 31, 2025.
- The company completed a business combination in February 2025, which was accounted for as a reverse recapitalization.
- The company's net loss for the quarter was $15,941,328, or $0.42 per share, compared to a net loss of $230,970, or $0.01 per share, for the same period in 2024.
- General and administrative expenses increased significantly to $15,073,548, primarily due to stock-based compensation and professional service fees.
- Research and development expenses also increased to $263,093 as the company continues to develop its products.
- Sales and marketing expenses increased to $219,839 due to increased marketing and investor awareness costs.
- The company's cash balance as of March 31, 2025, was $1,346,543.
- The company has a working capital deficit of $6,903,439 as of March 31, 2025.
- The company's future capital requirements will depend on many factors, including the timing and extent of spending to support further sales and marketing and research and development efforts.
- Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern through twelve months from the date these condensed consolidated financial statements are available to be issued.
Sentiment
Score: 2
Explanation: The document presents a highly negative outlook due to significant losses, a going concern warning, and Nasdaq listing deficiencies. While there are some positive developments in product development, the financial risks outweigh them.
Positives
- The company completed its business combination, providing access to additional capital.
- The company is actively developing its sublingual drug delivery technology and advancing its product pipeline.
- The company has entered into a Purchase Agreement (ELOC Agreement) with Arena Business Solutions Global SPC II, Ltd. (Arena) for up to $100,000,000.
Negatives
- The company reported a significant net loss of $15,941,328 for the quarter ended March 31, 2025.
- The company has a substantial working capital deficit of $6,903,439.
- The company's auditors have raised substantial doubt about its ability to continue as a going concern.
- The company received notices from Nasdaq regarding non-compliance with listing requirements.
Risks
- The company's ability to raise additional financing is uncertain, and failure to do so could adversely affect its business.
- The company faces intense competition in the biopharmaceutical industry.
- The company's success depends on obtaining and maintaining intellectual property protection for its drug candidates.
- The company's reliance on third-party manufacturers poses risks to its supply chain.
- The company's ability to regain compliance with Nasdaq listing requirements is uncertain.
- The company's liquidity condition raises substantial doubt about its ability to continue as a going concern.
Future Outlook
The company expects to generate revenue through developing and marketing drugs and nutraceuticals using the technology for the novel sublingual delivery. The company's future capital requirements will depend on many factors, including the timing and extent of spending to support further sales and marketing and research and development efforts. The company intends to raise such capital through issuances of additional equity.
Management Comments
- Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern through twelve months from the date these condensed consolidated financial statements are available to be issued.
Industry Context
The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and strong emphasis on proprietary products. The company faces potential competition from many sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and government agencies and public and private research institutions.
Comparison to Industry Standards
- The company's financial performance is significantly below industry standards for early-stage biopharmaceutical companies, particularly in terms of profitability and cash flow.
- Comparable companies, such as those developing novel drug delivery systems, typically have lower operating expenses and higher levels of funding.
- The company's reliance on debt financing and the associated high interest expense is not typical for companies in this sector.
- The company's going concern warning is a significant deviation from industry norms and raises serious concerns about its long-term viability.
Related Party Transactions
- The company assumed $353,679 of liabilities due to the sponsor of PowerUp and related to administrative services fees and a residual balance due from IPO proceeds.
- During the years ended 2024 and 2023, Aspire Biopharma, Inc incurred expenses and costs related to officer and director compensation, rental of office space, reimbursable expenses paid by affiliates and non interest bearing working capital loans.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and potential delisting from Nasdaq.
- Employees may be affected by potential cost-cutting measures or restructuring.
- Customers may be impacted by delays in product development or availability.
- Suppliers and creditors face increased risk of non-payment.
Next Steps
- The company is considering actions that it may take in response to these Notices to regain compliance with the continued listing requirements.
- The company intends to submit a section 505(b)(2) NDA for its high-dose aspirin product.
- The company plans to propose a later clinical trialfor purposes of further FDA applications (Trial 2) in approximately 24 healthy human volunteers to evaluate the pharmacodynamic effect of a single dose of Aspires high dose aspirin on platelet inhibition compared to that of standard oral aspirin.
Key Dates
| Date | Description |
|---|---|
| 2021-09 | Aspire Biopharma, Inc. was incorporated in Puerto Rico. |
| 2022-02-17 | Date of Warrant Agreement between PowerUp and Equiniti Trust Company, LLC. |
| 2023-03 | Company filed application number 63/456,290 with the United States Patent and Trademark Office (USPTO). |
| 2023-12-21 | PowerUp entered into a Loan and Transfer Agreement with the New Sponsor and SSVK Associates, LLC. |
| 2024-01-09 | PowerUp entered into a Loan and Transfer Agreement with the New Sponsor and Apogee Pharma. |
| 2024-01-10 | PowerUp entered into a Loan and Transfer Agreement with the New Sponsor and Jinal Sheth. |
| 2024-02-29 | Aspire Biopharma, Inc entered Corporate advisory agreement with an advisory firm. |
| 2024-03-05 | PowerUp entered into four separate First Subscription Agreements. |
| 2024-05-09 | PowerUp entered into four separate Second Subscription Agreements. |
| 2024-08-26 | PowerUp Acquisition Corp. entered into an Agreement and Plan of Merger. |
| 2024-09-27 | Aspire Biopharma, Inc issued three non-convertible 20 % original issues discount (OID) notes payable to related parties. |
| 2024-10-02 | Aspire Biopharma, Inc issued one non-convertible 20 % OID note payable to a related party for working capital. |
| 2024-10 | A second patent application was filed in October 2024 for a high-dose version of our sublingually administered aspirin product (application number 63/702,381). |
| 2024-12-03 | The Company entered into a second Loan and Transfer Agreement with the New Sponsor and Apogee Pharma (Apogee 2). |
| 2024-12-18 | PowerUp entered into a subscription agreement (the Blackstone Subscription Agreement) with Blackstone Capital Advisors, Inc. |
| 2024-12-30 | Aspire Biopharma, Inc issued one non-convertible 20 % OID note payable for working capital to a related party. |
| 2024-12-31 | Aspire Biopharma, Inc issued one non-convertible 20 % OID note payable for working capital to a related party. |
| 2025-01-03 | The agreed upon compensation was reduced to 4.75 % of the amount of shares outstanding after the close of the Business Combination. |
| 2025-01-21 | The 91,500,000 warrants were converted into 91,500,000 shares of Aspire Biopharma Inc. common stock. |
| 2025-01-22 | Aspire Biopharma, Inc issued one non-convertible 20 % OID note payable for working capital to a related party. |
| 2025-02-13 | PowerUp entered into a Purchase Agreement (ELOC Agreement) with Arena Business Solutions Global SPC II, Ltd. (Arena). |
| 2025-02-13 | Aspire Biopharma, Inc issued one non-convertible 20 % OID note payable for working capital to a related party. |
| 2025-02-17 | PowerUp Acquisition Corp. changed its name to Aspire Biopharma Holdings, Inc. |
| 2025-02-17 | The Company entered into a Securities Purchase Agreement (Securities Purchase Agreement) with Cobra Alternative Capital Strategies, LLC. |
| 2025-02-20 | The closing was consummated on February 20, 2025 (the SPA Closing) and the Company issued to the Investors Debentures in an aggregate principal amount of $3,750,000 (the Closing Debentures). |
| 2025-03-31 | End of the quarterly period. |
| 2025-04-01 | The Company received two default notices. |
| 2025-04-16 | The Company received two letters from the Nasdaq Stock Exchange LLC (Nasdaq). |
| 2025-04-24 | The Company entered into a settlement agreement (the Settlement Agreement) with Cobra Alternative Capital Strategies LLC, Blackstone Capital Advisors, Inc., and their affiliates (collectively, the Lenders). |
| 2025-05-13 | The Company filed a Registration Statement on Form S-1 to register 2,929,000 of the outstanding 9,763,333 Private Placement Warrants. |
| 2025-05-14 | Date of report. |
| 2025-06-30 | This clinical trial should end by June 30, 2025. |
| 2025-08-15 | Extending the earliest maturity date to August 15, 2025. |
| 2025-08-20 | The Lenders also agreed to enter into lock-up/leak-out agreements governing the sale of Company shares through August 20, 2025. |
| 2025-09-10 | Amending additional notes to extend their maturity dates to September 10, 2025. |
| 2025-10-01 | The Company further intends to file a PCT application on October 1, 2025, claiming priority to U.S. Application No. 63/702,381. |
| 2025-10-13 | Under Nasdaq Listing Rule 5810(c)(3)(C), the Company is entitled to a 180-day period, ending on October 13, 2025, to rectify the deficiency. |
| 2026 Q1/Q2 | Aspire intends to submit an NDA for the testosterone product under 505(b)(2) to the FDA in the first or second quarter of 2026. |
Keywords
Biopharma, Sublingual Delivery, Business Combination, Financial Results, Net Loss, Working Capital, Going Concern, Nasdaq, ELOC, Convertible Debentures, Pharmaceuticals, Research and Development
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.